Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 157Lung Neoplasms 73Small Cell Lung Carcinoma 52Neoplasms 8Melanoma 8Carcinoma, Renal Cell 7Squamous Cell Carcinoma of Head and Neck 6Mesothelioma, Malignant 6Mesothelioma 6Colorectal Neoplasms 6Carcinoma 6Breast Neoplasms 6Stomach Neoplasms 5Neoplasm Metastasis 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Respiratory Tract Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neoplasms by Site 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thoracic Neoplasms 3Respiratory Tract Diseases 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Esophageal Neoplasms 3Carcinoma, Merkel Cell 3Carcinoma, Bronchogenic 3Bronchial Neoplasms 3Adenocarcinoma of Lung 3

Interventions

durvalumab 2alfatide II 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Non-Small Cell Lung Cancer NSCLC × durvalumab × Thoracic × Clear all
NCT02879617 2024-01-05

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Academic Thoracic Oncology Medical Investigators Consortium

Phase 2 Completed
47 enrolled 34 charts
Thoracic

Non-Small Cell Lung Cancer NSCLC

NCT04667312 2023-10-02

CODAK

AstraZeneca

Completed
115 enrolled
Thoracic

Non-Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡